PRECISION BIOSCIENCES INC
For the period ended Sep 30, 2026. Filed Nov 3, 2026.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Sep 30, 2026 · Filed Nov 3, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Item 5. Other Information
Rule 10b5-1 Trading Plan
On July 10, 2026, Naresh Tanna, who was then serving as our Vice President of Investor Relations and Chief of Staff to our Chief Executive Officer and was appointed as our Chief Financial Officer on July 23, 2026, entered into a trading plan intended to satisfy the affirmative defense conditions under Rule 10b5-1(c). Mr. Tanna’s trading plan provides for the sale of, in the aggregate, up to 24,645 shares of our common stock from August 17, 2026 through September 30, 2027, unless the plan is earlier terminated. The 24,645 share aggregate limit represents the maximum number of shares that may be sold pursuant to Mr. Tanna’s Rule 10b5-1 plan. The actual number of shares sold will be dependent on the satisfaction of certain conditions set forth in the written plan.
On August 31, 2026, Mei Burris, our Chief Accounting Officer, entered into a trading plan intended to satisfy the affirmative defense conditions under Rule 10b5-1(c). Ms. Burris’s trading plan provides for the sale of, in the aggregate, up to 4,115 shares of our common stock from December 1, 2026 through November 30, 2027, unless the plan is earlier terminated. The 4,115 share aggregate limit represents the maximum number of shares that may be sold pursuant to Ms. Burris’s Rule 10b5-1 plan. The actual number of shares sold will be dependent on the satisfaction of certain conditions set forth in the written plan.
On September 4, 2026, Dario Scimeca, our Chief Legal Officer, entered into a trading plan intended to satisfy the affirmative defense conditions under Rule 10b5-1(c). Mr. Scimeca’s trading plan provides for the sale of, in the aggregate, up to 30,350 shares of our common stock from December 4, 2026 through November 30, 2027, unless the plan is earlier terminated. The 30,350 share aggregate limit represents the maximum number of shares that may be sold pursuant to Mr. Scimeca’s Rule 10b5-1 plan. The actual number of shares sold will be dependent on the satisfaction of certain conditions set forth in the written plan.
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.